Vipul Jairath

Vipul Jairath's AcademicInfluence.com Rankings

Vipul Jairath

Engineering

#7255

World Rank

#8619

Historical Rank

Cybernetics

#159

World Rank

#165

Historical Rank

Biomedical Engineering

#718

World Rank

#730

Historical Rank

Applied Physics

#2473

World Rank

#2514

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is Vipul Jairath Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vipul Jairath's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies (2014) (286)
Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group (2019) (232)
Development and validation of a histological index for UC (2015) (229)
Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial (2015) (193)
Systematic review with meta‐analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis (2017) (189)
Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology (2019) (160)
Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review (2019) (134)
Histologic scoring indices for evaluation of disease activity in ulcerative colitis. (2017) (133)
Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit (2017) (124)
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial (2020) (124)
An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease (2018) (120)
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. (2017) (116)
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. (2018) (111)
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. (2020) (108)
Acute severe ulcerative colitis: from pathophysiology to clinical management (2016) (107)
Global burden of inflammatory bowel disease. (2020) (104)
Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials (2015) (99)
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease (2017) (94)
HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial (2014) (87)
Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study (2012) (87)
Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. (2014) (86)
Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta‐analysis (2018) (86)
Narrow-band Imaging for Detection of Neoplasia at Colonoscopy: a Meta-analysis of Data From Individual Patients in Randomized Controlled Trials. (2019) (83)
Mortality From Acute Upper Gastrointestinal Bleeding in the United Kingdom: Does It Display a “Weekend Effect”? (2011) (82)
Histologic scoring indices for evaluation of disease activity in Crohn's disease. (2016) (82)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. (2018) (77)
National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non‐variceal upper gastrointestinal bleeding (2012) (73)
The emerging role of histologic disease activity assessment in ulcerative colitis. (2018) (72)
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? (2018) (70)
Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding (2013) (67)
Review article: dose optimisation of infliximab for acute severe ulcerative colitis (2017) (67)
Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. (2017) (66)
Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. (2017) (64)
Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials (2014) (62)
Strategies for detecting colon cancer in patients with inflammatory bowel disease. (2017) (62)
Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts. (2020) (59)
Increased risk of type I errors in cluster randomised trials with small or medium numbers of clusters: a review, reanalysis, and simulation study (2016) (58)
Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial (2015) (57)
Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease (2019) (55)
Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease (2018) (55)
Biosimilars in IBD: hope or expectation? (2013) (54)
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. (2020) (54)
Review article: pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases (2015) (53)
Patterns of blood component use in cirrhosis: a nationwide study (2016) (50)
HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease (2018) (50)
Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. (2016) (50)
ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study (2020) (48)
Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom (2013) (47)
Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A systematic review of cohort studies. (2012) (46)
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial (2018) (46)
Red cell transfusion for the management of upper gastrointestinal haemorrhage. (2010) (45)
Acute severe ulcerative colitis: latest evidence and therapeutic implications (2018) (44)
Reliability of histologic assessment in patients with eosinophilic oesophagitis (2018) (43)
Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. (2019) (43)
Morbidity and Mortality After Surgery for Nonmalignant Colorectal Polyps: A 10-Year Nationwide Analysis (2019) (41)
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review (2018) (41)
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. (2021) (40)
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? (2020) (40)
Innovations in Oral Therapies for Inflammatory Bowel Disease (2019) (39)
No Benefit of Concomitant 5‐Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials (2018) (39)
The development of a magnetic resonance imaging index for fistulising Crohn's disease (2017) (39)
Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey (2017) (39)
Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. (2019) (38)
Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis (2017) (38)
Improving outcomes from acute upper gastrointestinal bleeding (2012) (37)
Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. (2018) (37)
Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (37)
Development and Validation a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. (2019) (36)
Anticoagulation in patients with liver cirrhosis: complication or therapeutic opportunity? (2013) (36)
Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease (2017) (36)
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2019) (36)
Development of Clinical Prediction Models for Surgery and Complications in Crohn’s Disease (2018) (35)
Efficacy of Endoscopic Dilation of Gastroduodenal Crohn’s Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data (2018) (34)
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis (2020) (34)
Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. (2016) (34)
The safety of vedolizumab for the treatment of ulcerative colitis (2017) (33)
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial (2022) (33)
Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis (2017) (32)
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set (2017) (32)
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease (2020) (31)
Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians (2011) (31)
Antibiotics for induction and maintenance of remission in Crohn's disease. (2017) (30)
An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. (2021) (30)
Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease. (2020) (30)
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? (2019) (29)
OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study (2021) (29)
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials (2016) (29)
Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? (2014) (29)
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review (2018) (28)
Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta‐Analysis (2018) (28)
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis (2018) (28)
Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
Choosing appropriate analysis methods for cluster randomised cross‐over trials with a binary outcome (2016) (27)
Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. (2017) (27)
A comparison of approaches for adjudicating outcomes in clinical trials (2017) (26)
Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease (2019) (26)
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review (2019) (25)
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? (2019) (25)
Outcome measures in clinical trials of treatments for acute severe haemorrhage (2018) (25)
US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. (2019) (25)
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. (2018) (24)
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease (2021) (24)
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. (2021) (23)
Restrictive vs Liberal Blood Transfusion for Acute Upper Gastrointestinal Bleeding: Rationale and Protocol for a Cluster Randomized Feasibility Trial (2013) (23)
Development, Validation, and Comparative Assessment of an International Scoring System to Determine Risk of Upper Gastrointestinal Bleeding (2019) (23)
Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial (2019) (23)
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease (2020) (23)
Definitions of response and remission for the Robarts Histopathology Index (2018) (23)
Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease. (2019) (22)
Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT (2019) (22)
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis (2020) (21)
Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants. (2017) (21)
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease (2019) (21)
Poor Outcomes in Hospitalized Patients With Gastrointestinal Bleeding: Impact of Baseline Risk, Bleeding Severity, and Process of Care (2014) (21)
Standardising the interpretation of liver biopsies in non‐alcoholic fatty liver disease clinical trials (2019) (21)
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis (2020) (21)
Alicaforsen for the treatment of inflammatory bowel disease (2017) (20)
Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population‐based cohort (2019) (20)
Systematic Review: Patient Perceptions of Monitoring Tools in Inflammatory Bowel Disease (2020) (20)
Systematic review: medical therapy for fibrostenosing Crohn’s disease (2020) (20)
Modern‐day management of upper gastrointestinal haemorrhage (2015) (20)
Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). (2020) (20)
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease (2018) (20)
Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol (2018) (19)
Diagnostic and therapeutic treatment modalities for acute lower gastrointestinal bleeding: a systematic review (2017) (19)
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis (2021) (19)
Efficient Early Drug Development for Ulcerative Colitis. (2016) (19)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. (2021) (19)
Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials (2020) (19)
Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. (2019) (18)
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing (2020) (18)
Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies (2020) (18)
Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease (2017) (18)
Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. (2019) (18)
A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials (2018) (18)
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS) (2021) (17)
External Validation of the Oakland Score to Assess Safe Hospital Discharge Among Adult Patients With Acute Lower Gastrointestinal Bleeding in the US (2020) (17)
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. (2021) (17)
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease (2022) (17)
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease (2021) (16)
Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial (2013) (16)
How do we Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? (2019) (16)
Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis (2019) (16)
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study (2021) (16)
Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2019) (15)
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. (2019) (15)
Most noninferiority trials were not designed to preserve active comparator treatment effects. (2019) (15)
What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? (2019) (15)
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. (2020) (15)
Performance report cards increase adenoma detection rate (2017) (15)
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials. (2020) (14)
Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With infliximab. (2020) (14)
Pre-specification of statistical analysis approaches in published clinical trial protocols was inadequate. (2018) (14)
A product review of vedolizumab in inflammatory bowel disease (2019) (14)
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. (2020) (13)
Advances in transfusion medicine: gastrointestinal bleeding (2018) (13)
Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial (2019) (13)
Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. (2020) (12)
No increased risk of nephrotoxicity associated with 5‐aminosalicylic acid in IBD: a population‐based cohort and nested case‐control study (2019) (12)
Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis (2019) (12)
Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. (2020) (12)
Comparative outcomes in patients with ulcer‐ vs non‐ulcer‐related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients (2019) (12)
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2021) (11)
Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease (2018) (11)
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease (2021) (11)
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's disease: A Systematic Review. (2021) (11)
The overall approach to the management of upper gastrointestinal bleeding. (2011) (11)
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials (2021) (11)
Adalimumab for induction of remission in Crohn's disease. (2017) (11)
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. (2020) (10)
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis (2020) (10)
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. (2019) (10)
Outcomes following restrictive or liberal red blood cell transfusion in patients with lower gastrointestinal bleeding (2019) (10)
INTRAVENOUS USTEKINUMAB REINDUCTION IS EFFECTIVE IN PRIOR BIOLOGIC FAILURE CROHN'S DISEASE PATIENTS ALREADY ON 4 WEEKLY DOSING. (2020) (10)
Reporting of randomised factorial trials was frequently inadequate. (2020) (10)
No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy (2020) (9)
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. (2016) (9)
Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy (2018) (9)
Development of Anti-fibrotic Therapy in Stricturing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. (2021) (9)
Targeting anti-fibrotic pathways in Crohn's disease - The final frontier? (2019) (9)
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis (2021) (9)
Presence of Melena in Obscure Gastrointestinal Bleeding Predicts Bleeding in the Proximal Small Intestine (2018) (8)
Thrombelastography‐guided blood product use before invasive procedures in cirrhosis with severe coagulopathy (2016) (8)
Effect of restrictive versus liberal red cell transfusion strategies on haemostasis: systematic review and meta-analysis (2017) (8)
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score (2022) (8)
What is the role of histopathology in the evaluation of disease activity in Crohn's disease? (2019) (8)
Acute upper gastrointestinal bleeding—time for some new triggers? (2013) (8)
Adalimumab for maintenance of remission in Crohn's disease. (2017) (8)
Comparative Risk of Serious Infections with Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. (2022) (8)
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis (2021) (8)
Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. (2016) (8)
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study (2017) (8)
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. (2017) (8)
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study (2020) (8)
W1038 Acute Upper Gastrointestinal Bleeding – Why Do Patients Die? (2010) (7)
Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn’s disease (2017) (7)
Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis. (2021) (7)
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. (2020) (7)
The optimal use of blood components in the management of gastrointestinal bleeding. (2019) (7)
Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. (2019) (7)
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial) (2022) (7)
The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. (2017) (7)
The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment) (2022) (7)
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials (2021) (7)
Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease (2018) (7)
Improving Clinical Trial Efficiency in Gastroenterology. (2019) (7)
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. (2019) (7)
Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study (2018) (7)
Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. (2021) (7)
Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. (2021) (7)
Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding (2017) (6)
External validation of the international bleeding risk score in both upper and lower GI bleeding: An international multicentre study (2018) (6)
Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol (2018) (6)
Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2021) (6)
Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis (2021) (6)
Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn’s disease of the pouch (2018) (6)
Study protocol: first nationwide comparative audit of acute lower gastrointestinal bleeding in the UK (2016) (6)
Identifying Outcomes in Clinical Trials of Fistulizing Crohn's Disease for the Development of a Core Outcome Set. (2019) (6)
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. (2019) (6)
1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis (2019) (5)
Endoscopic glue injection for persistent biliary leakage. (2009) (5)
Effectiveness of Re-induction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. (2021) (5)
Reliability and Responsiveness of Endoscopic Disease Activity Assessment in Eosinophilic Esophagitis. (2022) (5)
Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes (2020) (5)
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease (2022) (5)
Mo1801 – Incorporating Fecal Calprotectin in Clinical Practice in Patients with Ulcerative Colitis: A Grade-Based Approach (2019) (5)
Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. (2021) (5)
RESTRICTIVE VERSUS LIBERAL BLOOD TRANSFUSION FOR ACUTE UPPER GASTROINTESTINAL BLEEDING (TRIGGER): PRAGMATIC, CLUSTER RANDOMISED, FEASIBILITY TRIAL (2014) (5)
KODA score: an updated and validated bowel preparation scale for patients undergoing small bowel capsule endoscopy (2020) (5)
Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis (2021) (5)
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review (2021) (4)
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. (2022) (4)
Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease. (2021) (4)
Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis (2017) (4)
Su1838 – Comparative Risk of Serious Infections with Biologic And/Or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis (2019) (4)
The relationship between endoscopic and clinical recurrence in postoperative Crohn's disease: a systematic review and meta-analysis. (2021) (4)
Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. (2020) (4)
A randomized controlled trial of high volume simethicone to improve visualization during capsule endoscopy (2021) (4)
684 Evaluation of Global Coagulation Profiles in Patients With Acute Severe Colitis: Implications for Thromboprophylaxis (2015) (4)
Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy. (2020) (4)
Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn’s Disease After Elective Surgery: Meta-Analysis (2021) (4)
Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series (2022) (4)
UEG Week 2016 Poster Presentations (2016) (4)
Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn's disease: Meta-analysis of Randomised controlled trials. (2021) (4)
Disease Activity Indices for Pouchitis: A Systematic Review. (2021) (4)
Systematic review: disease activity indices for immune checkpoint inhibitor‐associated enterocolitis (2021) (4)
637 Clinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease (2019) (4)
Lower 90-day Hospital Readmission Rates for Esophageal Variceal Bleeding After TIPS (2020) (4)
Reliability of EUS indices to detect inflammation in ulcerative colitis. (2017) (4)
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease. (2022) (4)
Evolution of treatment targets in Crohn's disease. (2019) (4)
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease. (2022) (4)
OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial (2022) (4)
Platelet transfusion for the actively bleeding patient (2013) (3)
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives (2016) (3)
Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. (2022) (3)
Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. (2021) (3)
High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. (2021) (3)
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis (2022) (3)
* Red cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding- a survey of 815 clinicians (2011) (3)
PTU-185 Update On The Halt-it Trial Progress: Tranexamic Acid For The Treatment Of Gastrointestinal Haemorrhage – An International, Randomised, Double Blind Placebo Controlled Trial (2014) (3)
Proactive Therapeutic Drug Monitoring vs. Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. (2022) (3)
116 Red Blood Cell Transfusions are Associated With Increased Rebleeding in Patients With Nonvariceal Upper Gastrointestinal Haemorrhage (2012) (3)
PWE-295 Thrombin generation is normal in cirrhotics with acute variceal haemorrhage: results from a prospective study (2012) (3)
A Randomized Trial of Vedolizumab Dose Optimization in Patients With Moderate to Severe Ulcerative Colitis Who Have Early Nonresponse and High Drug Clearance: The ENTERPRET Trial. (2022) (3)
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. (2021) (3)
Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States. (2020) (3)
Withdrawal of drug therapy for patients with quiescent Crohn's disease (2017) (3)
Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. (2020) (3)
Underrepresentation of minorities and under-reporting of race and ethnicity in Crohn's Disease clinical trials. (2021) (3)
Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. (2018) (3)
Non‐invasive monitoring and treat‐to‐target approach are cost‐effective in patients with mild–moderate ulcerative colitis (2022) (2)
Hyperbaric Oxygen for Hospitalized patients with Ulcerative Colitis. (2018) (2)
Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE‐HSS)—an important first step. Authors’ reply (2018) (2)
A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares (2020) (2)
Can we reduce bias in open-label trials when blinded outcome assessment is not possible? An example from the trigger trial (2015) (2)
Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity (2012) (2)
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. (2021) (2)
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease (2021) (2)
Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center. (2022) (2)
Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2011) (2)
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. (2022) (2)
Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease (2022) (2)
Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod (2019) (2)
A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. (2021) (2)
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review (2022) (2)
Sa1034 Microparticle Dependent Procoagulant Activity and Thrombin Generation is Increased in Patients With Cirrhosis Induced Coagulopathy (2012) (2)
Infliximab for maintenance of remission in Crohn's disease (2017) (2)
Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. (2022) (2)
Su1910 EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS TREATED-TO-TARGET: COMPARISON OF CLINICAL VS ENDOSCOPIC VS HISTOLOGIC REMISSION (2020) (2)
Editorial: treating strictures in inflammatory bowel disease—authors’ reply (2018) (2)
No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy (2021) (2)
Su1802 Prevalence, Management and Outcomes of Patients With Coagulopathy Following Acute Non-Variceal Upper Gastrointestinal Bleeding (2012) (2)
112 Mortality From Acute Upper Gastro-Intestinal Bleeding in the UK – Does it Display a “Weekend Effect”? (2010) (2)
Editorial: the impact of the placebo effect in Crohn's disease – author's reply (2017) (2)
Uncertainty in transfusion practice for acute upper gastrointestinal bleeding (AUGIB): implications for clinical trial design (2011) (2)
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium (2022) (2)
Early coagulopathy is associated with increased mortality and re-bleeding in non-cirrhotics with acute upper gastrointestinal bleeding (2010) (2)
A multi-omic analysis reveals the esophageal dysbiosis as the predominant trait of eosinophilic esophagitis (2023) (2)
Letter: dose optimising infliximab in acute severe ulcerative colitis – authors' reply (2017) (2)
132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE (2021) (2)
Nonvariceal upper GI bleeding: it's not just about peptic ulcers. (2012) (2)
P120 Prevalence of endoscopic improvement and endoscopic remission according to patient reported outcomes in ulcerative colitis (2020) (2)
A114 SYSTEMATIC REVIEW AND META-ANALYSIS: ENDOSCOPIC AND HISTOLOGIC PLACEBO RATES IN INDUCTION AND MAINTENANCE TRIALS OF ULCERATIVE COLITIS (2018) (2)
Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
Cochrane Database of Systematic Reviews Strategies for detecting colon cancer in patients with inflammatory bowel disease (Review) (2017) (2)
Patient’s Perspective on Disease Burden, Remission Definition, and Symptoms Associated With Treatment Seeking: A Qualitative Study in Adult and Adolescent Patients With Crohn’s Disease (2020) (2)
Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions (2020) (2)
Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn's Disease. (2020) (2)
Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series. (2020) (2)
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview (2017) (2)
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. (2022) (1)
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo (2023) (1)
Letter: predicting azathioprine‐associated pancreatitis in IBD—phenotype or genotype? Authors' reply (2018) (1)
Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s disease (2017) (1)
P473 Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic (2018) (1)
Editorial: blood transfusion for lower gastrointestinal bleeding—authors’ reply (2019) (1)
334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis (2019) (1)
Placebo rates in randomized controlled trials of proctitis therapy: A systematic review and meta-analysis. (2022) (1)
Letter: is blood transfusion really a risk factor for rebleeding in nonvariceal gastrointestinal bleeding? Authors’ reply (2013) (1)
Risk Stratification in Cancer Patients with Acute Upper Gastrointestinal Bleeding: Comparison of Glasgow-Blatchford, Rockall and AIMS65, and Development of a New Scoring System (2022) (1)
Discordance Between Patient-Reported Outcomes and Endoscopic Inflammation in Mild-to-Moderate Ulcerative Colitis (2021) (1)
DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) (1)
Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. (2021) (1)
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease. (2022) (1)
Tofacitinib Induced Long-term Clinical, Endoscopic, and Histological Remission as a 6th Line Agent in Medically Refractory Ulcerative Colitis. (2020) (1)
Comparison of Risk Scores for Lower Gastrointestinal Bleeding (2022) (1)
937 ROTATIONAL THROMBOELASTOMETRY IN CIRRHOSIS: THE CLOT THICKENS! (2011) (1)
611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE (2021) (1)
Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators (2021) (1)
Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy. (2021) (1)
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission (2023) (1)
The impact of symptom severity on the humanistic and economic burden of inflammatory bowel disease: a real-world data linkage study (2022) (1)
Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies (2019) (1)
Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs. (2022) (1)
OP10 Comparative efficacy of biologics for endoscopic healing of the ileum and colon in Crohn’s Disease (2022) (1)
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (1)
Extending evidence for the use of tranexamic acid from traumatic haemorrhage to other patients with major bleeding: do we need more than one haemorrhage protocol? The case of gastrointestinal bleeding (2015) (1)
Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. (2018) (1)
P203 The performance of the Rutgeerts’ score, SES-CD, and MM-SES-CD for prediction of post-operative clinical recurrence in Crohn’s disease (2022) (1)
* What role does surgery play in the modern day management of non-variceal upper gastrointestinal bleeding? (2011) (1)
P190 Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease (2020) (1)
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel (2022) (1)
P081 HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES FOR ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2019) (1)
Coagulopathy and bleeding in liver disease (2015) (1)
A nonparametric approach to confidence intervals for concordance index and difference between correlated indices (2022) (1)
OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2012) (1)
The case for universal access to tranexamic acid (2012) (1)
Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: Results from a systematic review of induction studies. (2022) (1)
A98 PLASMA BIOMARKER MAY DETECT DISEASE-DEPENDENT ALTERATIONS IN GUT MICROBIOTA IN IBD: A PILOT STUDY (2018) (1)
Development of a Global Rating Scale for Inflammatory Bowel Disease (2019) (1)
Tu1598 Acute Variceal Bleeding in the UK: Clinical Characteristics, Endoscopic Therapy and Predictors of Outcomes (2012) (1)
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance (2022) (1)
Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis (2015) (1)
Is it time to include older adults in inflammatory bowel disease trials? A call for action. (2022) (1)
W1039 Can We Predict Length of Stay in Patients Admitted With Acute Upper Gastrointestinal Bleeding (2010) (1)
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis (2022) (1)
Efficacy and Safety of Oral Janus Kinase Inhibitors for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2019) (1)
540 Thrombin Generation is Normal in Cirrhotics Presenting With Acute Variceal Haemorrhage: Results From a Prospective Study (2012) (1)
Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis (2021) (1)
Mo1916 – Effectiveness and Safety of Ustekinumab for Crohn’s Disease in Routine Clinical Practice (2019) (1)
Letter: pre‐operative anti‐TNF therapy in Crohn’s disease is not associated with increased complications following elective surgery (2019) (1)
330 Comparison of Glasgow-Blacthford, Rockall and Aims65 Scores for Predicting Upper GI Bleeding Outcomes in Patients With Cancer (2017) (1)
Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis. (2020) (1)
884a: THE IDEAL STUDY: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL α4β7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (2022) (1)
Su1062 Placebo Response and Remission Rates in Ulcerative Colitis Clinical Trials: Systematic Review and Meta-Analysis (2015) (1)
P405 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based study (2018) (1)
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease. (2022) (1)
Sa1814 – Early Combined Immunosuppression is More Effective for Reducing Crohn's Disease Related Complications in Isolated Colonic Than Ileal Dominant Crohn's: Post-Hoc Analysis of React Trial (2019) (1)
Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier's Disease in a Patient With Ulcerative Colitis. (2021) (1)
Editorial: histologic normalisation in ulcerative colitis (2020) (1)
Existing Bowel Preparation Quality Scales Are Reliable in the Setting of Centralized Endoscopy Reading (2022) (0)
P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis (2023) (0)
PATIENT PERSPECTIVE OF BOWEL URGENCY AND BOWEL URGENCY-RELATED ACCIDENTS IN CROHN’S DISEASE (2023) (0)
P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study. (2017) (0)
A306 SIBO AND ASSOCIATION WITH IBD ACTIVITY. (2018) (0)
A156 CONTRASTING THE USE OF 5-ASA IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS AT A TERTIARY CARE IBD CLINIC (2018) (0)
Declining enrolment and other challenges in IBD clinical trials: Causes and potential solutions. (2023) (0)
Infliximab for induction of remission in Crohn's disease (2017) (0)
Editorial: use of intestinal ultrasound in the scoring of Crohn’s disease activity in clinical trials – is it ready for prime time yet? Authors’ reply (2021) (0)
Su484 AN INTERNATIONAL CONSENSUS TOWARD STANDARDIZATION OF HISTOPATHOLOGIC SCORING FOR SMALL BOWEL STRICTURES IN CROHN'S DISEASE (2021) (0)
A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE (2019) (0)
PTH-019 Mortality from acute upper gastro-intestinal bleeding in the UK: does it display a “weekend effect”? (2010) (0)
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease (2021) (0)
709 Optimizing the Definition of Clinical Response Using the Modified Mayo Score: An Analysis of a Phase 2 Study With Mirikizumab in Patients With Ulcerative Colitis (2019) (0)
S0819 Evaluating Cost Per Remission and Cost of Serious Adverse Events in Advanced Therapies for Ulcerative Colitis (2020) (0)
The Impact of Multidisciplinary Conferences on Treatment Plans for Patients With Inflammatory Bowel Disease in a Tertiary Canadian Centre (2021) (0)
OC-023 Can we predict length of stay in patients admitted with acute upper gastrointestinal bleeding? (2010) (0)
Mo1462: DEVELOPMENT OF A MAGNETIC RESONANCE ENTEROGRAPHY INDEX FOR ASSESSING SMALL BOWEL STRICTURES IN PATIENTS WITH CROHN'S DISESE: VALIDATION OF METHODS AND ITEM RELIABILITY (2022) (0)
Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. (2019) (0)
Demystifying estimands in cluster-randomised trials (2023) (0)
A126 SAFETY OF COMBINATION BIOLOGIC AND IMMUNOSUPPRESSIVE THERAPY POST-ORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW (2019) (0)
209 – Early Combined Immunosuppression is Effective and Safe in Older Patients with Crohn's Disease: Post-Hoc Analysis of React Cluster Randomized Trial (2019) (0)
Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score (2022) (0)
Transfusion in Gastrointestinal Bleeding (2015) (0)
PWE-294 Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy (2012) (0)
A214 A COMPARISON OF REAL-WORLD UTILIZATION PATTERNS OF INNOVATOR AND BIOSIMILAR INFLIXIMAB: A PRESCRIPTION CLAIMS DATA SUBGROUP ANALYSIS OF GERMAN GASTROENTEROLOGISTS (2018) (0)
Vedolizumab for the Treatment of Chronic Pouchitis. (2023) (0)
AJG-22-0909 121..128 (0)
A92 ANTIBIOTICS FOR INDUCTION AND MAINTENANCE OF REMISSION IN CROHN’S DISEASE (2018) (0)
S819 Incidence, Outcomes, and Impact of COVID-19 on Inflammatory Bowel Disease: Propensity Matched Analysis of a Large Research Network (2021) (0)
Comparative Speed of Early Symptomatic Remission with Advanced Therapies for Moderate-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. (2023) (0)
Editorial: gut selective immunosuppression—is it a double edged sword? Authors’ reply (2017) (0)
Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm (2023) (0)
Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol (2018) (0)
PTH-020 Acute upper gastrointestinal bleeding: why do patients die? (2010) (0)
SAFE DISCHARGE AFTER ACUTE LOWER GASTROINTESTINAL BLEEDING : 1 DESIGN AND VALIDATION OF A NEW VALIDATED RISK SCORE 2 3 4 (2017) (0)
A134 ANTI-IL-12/23P40 ANTIBODIES FOR MAINTENANCE OF REMISSION IN CROHN’S DISEASE (2018) (0)
DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes. (2017) (0)
Mo1119 Performance of Glasgow-Blacthford, Rockall and Aims65 Scores to Identify the Low-Risk Group After Upper Gastrointestinal Bleeding in Patients With Cancer (2017) (0)
Tu1440: LONG-TERM CUMULATIVE SAFETY OF USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS (2022) (0)
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease (2021) (0)
A113 ANNUAL COLONOSCOPY VOLUME IS NOT PREDICTIVE OF COLONOSCOPY QUALITY - FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT (2021) (0)
P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis (2023) (0)
S749 Mirikizumab Improves Work Productivity and Activity Impairment Questionnaire Scores in Moderately-to-Severely Active UC: The LUCENT-1 and LUCENT-2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies (2022) (0)
AJG-20-3412 1709..1719 (0)
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index. (2023) (0)
P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index (2023) (0)
S0867 The Association Between Patient Activation and Health-Related Quality of Life Among Individuals With Crohn’s Disease (2020) (0)
Su1861 – Comparative Efficacy and Speed of Onset of Infliximab Versus Golimumab in Ulcerative Colitis: A Patient-Level Analysis of Clinical Trials (2019) (0)
Food Insecurity Negatively Impacts Gluten Avoidance and Nutritional Intake in Patients With Celiac Disease (2021) (0)
P404 Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials (2022) (0)
Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy. (2022) (0)
PTU-148 Healthcare Costs And Quality Of Life Associated With Acute Upper Gastrointestinal Bleeding In The Uk (2014) (0)
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study (2022) (0)
P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis (2022) (0)
Tu1460: SENSITIVITY OF CLINICAL, ENDOSCOPIC, AND HISTOLOGIC REMISSION FOR DETECTION OF DRUG EFFICACY IN ULCERATIVE COLITIS TRIALS: A SYSTEMATIC REVIEW (2022) (0)
Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis. (2023) (0)
Editorial: assessing histological disease activity in Crohn’s disease—a call for standardisation of mucosal biopsy location. Authors' reply (2019) (0)
Mo1543: REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN CANADA (2022) (0)
A96 ADALIMUMAB FOR MAINTENANCE OF REMISSION IN CROHN’S DISEASE (2019) (0)
Mo1711 EXTERNAL VALIDATION OF THE OAKLAND SCORE IN 38,067 PATIENTS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING (2020) (0)
P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
Gastrointestinal bleeding (2012) (0)
Response to prothrombin complex concentrate to correct acquired abnormalities of the clotting screen in patients with liver impairment (2017) (0)
Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease? Authors’ reply (2022) (0)
584: VEDOLIZUMAB INTRAVENOUS IS EFFECTIVE ACROSS MULTIPLE TREATMENT TARGETS IN CHRONIC POUCHITIS: RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EARNEST TRIAL (2022) (0)
P666 Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review (2019) (0)
Patients with Crohn's disease and permanent ileostomy are universally excluded from clinical trials: A systematic review. (2023) (0)
Sa1051 WHAT IS THE IMPACT OF TRAINEE PARTICIPATION ON COLONOSCOPY QUALITY - FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT (2020) (0)
Response to Gupta and Hanauer (2019) (0)
EE227 Healthcare Resource Utilization and Costs Among Patients with Moderately-to-Severely Active Crohn’s Disease Treated with Ustekinumab: Real-World Evidence (2022) (0)
P462 Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders (2023) (0)
Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression. (2022) (0)
A136 PREDICTING THE NEED FOR MEDICAL RESCUE IN PATIENT ADMITTED WITH ACUTE SEVERE ULCERATIVE COLITIS (2018) (0)
P242 Universal exclusion of patients with Permanent Ileostomy in Crohn’s disease clinical trials: A systematic review (2023) (0)
Centrally-Determined Standardization of Flow Cytometry Methods Reduces Inter-Laboratory Variation in a Prospective Multicenter Study (2017) (0)
Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB (2021) (0)
A71 POLYP TO ADENOMA CONVERSION FACTOR AS A SURROGATE FOR ADENOMA DETECTION RATE-– FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT (2022) (0)
A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION (2022) (0)
Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis (2023) (0)
Access to unpublished protocols and statistical analysis plans of randomised trials (2022) (0)
1107 - Red Blood Cell Transfusion and Rebleeding Risk in Patients with Lower Gastrointestinal Bleeding (2018) (0)
Editorial: evolving histological assessment of NASH. Authors' reply (2019) (0)
Sa108 A SYSTEMATIC REVIEW AND META-ANALYSIS OF LOWER GASTROINTESTINAL BLEEDING RISK SCORES TO PREDICT ADVERSE OUTCOMES (0)
Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials—a missing link. Authors' reply (2021) (0)
A234 CLINICAL, ENDOSCOPIC AND HISTOLOGICAL IMPROVEMENT IN COMMON VARIABLE IMMUNODEFICIENCY DISEASE ASSOCIATED ENTEROPATHY WITH VEDOLIZUMAB (2020) (0)
Design of Clinical Trials in Gastrointestinal Bleeding (2012) (0)
Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn’s Disease Biopsies (2022) (0)
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis (2022) (0)
S735 Mirikizumab Improves Quality of Life in Moderately-to-Severely Active UC: Improvement in IBDQ Scores in Participants of LUCENT-1 and LUCENT-2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials (2022) (0)
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2022) (0)
Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. (2022) (0)
A145 “REAL WORLD” SAFETY AND EFFECTIVENESS OF VEDOLIZUMAB FOR ULCERATIVE COLITIS: RETROSPECTIVE STUDY FROM A TERTIARY CARE CANADIAN CENTRE (2018) (0)
Tu1461: LACK OF RACE/ETHNICITY REPORTING AND UNDERREPRESENTATION OF MINORITIES IN ULCERATIVE COLITIS DRUG DEVELOPMENT CLINICAL TRIALS (2022) (0)
Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. (2019) (0)
Case Report: Managing Postoperative Crohn's Disease. (2022) (0)
P146 Comparison of three histologic indices in ulcerative colitis: Evaluation from the Phase 2 study of upadacitinib (U-ACHIEVE) (2020) (0)
Development of a Magnetic Resonance Imaging Index for Fistulising Crohn’s Disease Running title: MRI Index for Fistulising CD Authors: (2017) (0)
Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2019) (0)
P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy (2019) (0)
P039 Integrating Maintenance Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: A Network Meta-Analysis (2019) (0)
OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO) (2023) (0)
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn’s Disease (2022) (0)
A113 TEDUGLUTIDE IN PATIENTS WITH ACTIVE CROHN’S DISEASE AND SHORT BOWEL SYNDROME (2019) (0)
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis (2023) (0)
A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS (2023) (0)
Su1852 – Post-Operative Complications Following Elective Surgery in Inflammatory Bowel Disease Patients Receiving Biologic Therapy: A Systematic Review and Meta-Analysis (2019) (0)
P492 A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials (2022) (0)
P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease (2019) (0)
Preface - Gastrointestinal bleeding. (2019) (0)
P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis (2023) (0)
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease (2021) (0)
A166 CANNABIS USE IN CANADIAN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE FOLLOWING LEGALIZATION OF CANNABIS (2022) (0)
A117 PROPOFOL SEDATION DOES NOT IMPROVE MEASURES OF COLONOSCOPY QUALITY – FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT (2021) (0)
DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI) (2023) (0)
Design of clinical trials for mild-to-moderate Crohn's disease. (2022) (0)
Su1913 MAGNITUDE OF INCREMENTAL BENEFIT OF ACHIEVING DEEPER ENDOSCOPIC AND HISTOLOGIC TREATMENT TARGETS IN PATIENTS WITH ULCERATIVE COLITIS IN STRIDE-DEFINED REMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? (2020) (0)
Editorial: faecal microbiota transplantation for ulcerative colitis—not quite there yet? Authors’ reply (2017) (0)
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. (2023) (0)
OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2012) (0)
Mo1824 – Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2019) (0)
Letter: immunogenicity of anti‐TNF in elderly IBD patients—authors' reply (2019) (0)
OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial (2023) (0)
Su1866 – Integrating Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: Results from a Network Meta-Analysis (2019) (0)
S0662 Evaluating the Optimum Number of Biopsies to Assess Histologic Inflammation in Ulcerative Colitis (2020) (0)
A276 CLINCAL PREDICTORS FOR SESSILE SERRATED ADENOMA DETECTION: AN ANALYSIS OF 17,524 COLONOSCOPIES (2019) (0)
Placebo response rates in randomized controlled trials for perianal Crohn's disease: A systematic review and meta-analysis. (2022) (0)
Early combined immunosuppression reduces complications in long-standing Crohn's disease: a post hoc analysis of REACT. (2020) (0)
Methods for handling missing segments in Crohn’s disease clinical trials: analysis from the EXTEND trial (2021) (0)
Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. (2022) (0)
Response to Gupta and Hanauer. (2019) (0)
A111 INFLIXIMAB FOR INDUCTION OF REMISSION IN CROHN’S DISEASE (2018) (0)
Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis. (2023) (0)
Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease (2019) (0)
P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial (2023) (0)
713 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Influence of Immunosuppressants at Baseline (2019) (0)
PWE-184 Prevalence, management and outcomes of patients with coagulopathy following acute non-variceal upper gastrointestinal bleeding (2012) (0)
P311 Reliability of computed tomography enterography for evaluation of stricturing Crohn’s disease: Development of a Crohn’s disease stricture index (2023) (0)
S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study (2022) (0)
Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs. (2023) (0)
Authors' response (2011) (0)
CO95 A Matching-Adjusted Indirect Comparison of Filgotinib Versus Tofacitinib for Moderately to Severely Active Ulcerative Colitis (2022) (0)
HLA-DQA1*05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis. (2023) (0)
Tu1479: NORMALISATION OF BIOMARKERS AND IMPROVEMENT IN CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE TREATED WITH RISANKIZUMAB IN THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES (2022) (0)
DOP39 Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience (2019) (0)
P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease (2023) (0)
AJG-21-0877 264..271 (0)
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis (2022) (0)
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis—authors' reply (2021) (0)
Economic evaluation of tranexamic acid for the treatment of acute gastrointestinal bleeding: a cost-effectiveness analysis using data from the HALT-IT randomised controlled trial (2022) (0)
P038 Comparing the Efficacy and Safety of Subcutaneous Vedolizumab Versus Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-Analysis (2019) (0)
Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone (2023) (0)
Extended delay in endoscopic mucosal resection is not associated with adverse outcomes – Findings from the COVID-19 pandemic (2023) (0)
PGI46 DISEASE BURDEN, SYMPTOMS ASSOCIATED WITH TREATMENT-SEEKING AND REMISSION DEFINITION: A QUALITATIVE STUDY IN ADULT AND ADOLESCENT PATIENTS WITH CROHN'S DISEASE (2019) (0)
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy (2023) (0)
Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management (2022) (0)
An expert consensus to standardize definitions , diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn ’ s disease SHORT TITLE : Novel anti-fibrotics for Crohn ’ s disease (2018) (0)
SAT0209 A comparative real-world utilization patterns of innovator and biosimilar infliximab in a treatment naÏve and switch population from germany: a prescription claims analysis (2018) (0)
Tu1726 – The Impact of Early Disease Control with Vedolizumab on Surgery Rates Among Patients with Crohn's Disease: A Post Hoc Analysis of the Gemini Trials (2019) (0)
S754 Impact of Mirikizumab Treatment on Health-Related Quality of Life in Patients With Crohn’s Disease: A Phase 2 Study Analysis Using the SF-36 (2022) (0)
The clinical significance of eosinophils in ulcerative colitis: a systematic review. (2022) (0)
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis (2023) (0)
Treatment Targets in Ulcerative Colitis. (2016) (0)
Enhanced thrombin generation in cirrhotics with coagulopathy and variceal bleeding (2011) (0)
Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. Authors' reply (2021) (0)
A114 AN UNUSUAL CASE OF BLOW-OUT PERFORATION OF A DEFUNCTIONED STOMACH POST ROUX-EN-Y GASTRIC BYPASS DUE TO CROHN’S DISEASE (2019) (0)
P772 Association of histological remission with long-term clinical outcomes in patients with ulcerative colitis: a multi-national retrospective study with centralized histological assessment (2023) (0)
Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis? (2014) (0)
A180 SENSITIVITY AND SPECIFICITY OF LOWER GASTROINTESTINAL BLEEDING SCORES TO PREDICT ADVERSE OUTCOMES: SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis (2023) (0)
Endoscopy unit level interventions to improve adenoma detection rate - a systematic review and meta-analysis. (2023) (0)
Editorial: combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Authors' reply (2019) (0)
Su1958 CUMULATIVE RISK OF SURGERY IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE IN POPULATION-BASED COHORTS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TIME-TREND ANALYSIS (2020) (0)
Revisiting triggers: Optimal thresholds for transfusion in gastrointestinal bleeding may be higher than restrictive guidelines. (2022) (0)
Acute Non-Variceal Gastrointestinal Hemorrhage: Treatment (2019) (0)
PTU-184 Restrictive Versus Liberal Blood Transfusion For Acute Upper Gastrointestinal Bleeding: Cluster Randomised Feasibility Trial (2014) (0)
A200 VEDOLIZUMAB IS AN EFFECTIVE TREATMENT OPTION FOR NON INFLAMMATORY BOWEL DISEASE RELATED ENTEROPATHY (2021) (0)
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients (2023) (0)
A97 HLA-DQA1-HLA-DRB1 POLYMORPHISM IS A MAJOR PREDICTOR OF AZATHIOPRINE-INDUCED PANCREATITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2018) (0)
Preface - Evolving approaches to the evaluation and management of Crohn's disease. (2019) (0)
Assessment of Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients with ‘Early Diseaseʼ: Results of a Systematic Literature Review (2018) (0)
P325 Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis (2019) (0)
Acute upper gastrointestinal bleeding in the United Kingdom : improving outcomes (2013) (0)
Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease (2021) (0)
Editorial: aminosalicylates in Crohn's disease—prevalence, risks, costs and time to reassess? Authors’ reply (2018) (0)
Mo1100 PROPOSED CLINICAL MODEL FOR PREDICTION OF HEMOSTATIC THERAPY FOR UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH CANCER (2018) (0)
A125 PERIOPERATIVE ANTI-TNFα AGENTS AND POST-OPERATIVE INFECTIOUS COMPLICATIONS IN ELECTIVE SURGICAL IBD PATIENTS (2019) (0)
770 Relationship Between Protocol Specified Corticosteroid Tapering Regimens and Achieving Outcome Measures in Patients With Moderate-Severe Ulcerative Colitis and Crohn's Disease (2019) (0)
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. (2022) (0)
Fr624 NO EVIDENCE OF A FRIDAY EFFECT ON COLONOSCOPY QUALITY OUTCOMES (2021) (0)
Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials. (2022) (0)
A86 CANNABIS USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS HIGHER FOLLOWING LEGALIZATION OF CANNABIS IN CANADA AND IS ASSOCIATED WITH LOWER QUALITY OF LIFE (2023) (0)
Tu1533 A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL OF HIGH VOLUME SIMETHICONE TO IMPROVE VISUALIZATION DURING SMALL INTESTINAL CAPSULE ENDOSCOPY (2020) (0)
Association of Trainee Participation in Colonoscopy Procedures With Quality Metrics (2022) (0)
' s response to reviews Title : The risks and rewards of covariate adjustment in randomised trials : an assessment of 12 outcomes from 8 studies (2014) (0)
P479 Reliability and responsiveness of histologic disease activity indices in Crohn’s Disease (2023) (0)
S753 Mirikizumab Significantly Improves Abdominal Pain in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies (2022) (0)
S983 Baseline Demographics and Disease Characteristics of Patients With Ulcerative Colitis Who Responded to Vedolizumab at Week 6 (2022) (0)
* Outcomes following acute variceal bleeding in the 2007 UK national audit (2011) (0)
Exploring non-compliance in a cluster randomised feasibility study to inform the design of the phase III trial (2015) (0)
S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study (2022) (0)
HTH-5 Could machine learning (ML) improve indices for predicting outcome of AUGIB? (2021) (0)
PATIENT PERSPECTIVES OF BOWEL URGENCY AND BOWEL URGENCY-RELATED ACCIDENTS IN ULCERATIVE COLITIS (2023) (0)
Mo1917 - 5-Asa Prescription Trends over Time in Inflammatory Bowel Disease 1996-2015 - A UK Population-Based Study (2018) (0)
New oral anticoagulants in patients with atrial fibrillation (2014) (0)
S747 Mirikizumab Improves Mental and Physical Health Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vipul Jairath?

Vipul Jairath is affiliated with the following schools:

University of Western Ontario
University of Oxford
University of British Columbia
King Abdulaziz University

Vipul Jairath's Academic­Influence.com Rankings

Why Is Vipul Jairath Influential?

Vipul Jairath's Published Works

Published Works

What Schools Are Affiliated With Vipul Jairath?

Vipul Jairath's AcademicInfluence.com Rankings